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BACKGROUND: Assisted hatching (AH) techniques, designed for facilitating the embryo escape out of the zona
pellucida (ZP) have been used in IVF centres since 1992. The initial indications for AH were patient’s age, ZP
thickness, high basal FSH and repeated IVF failures. Several retrospective and prospective studies assessing AH
in these indications have given disparate results. Our aims were to evaluate the benefits of AH and immunosupp-
ressive/antibiotic treatment (IA) in patients with either a poor prognosis of success, previous implantation failures
or transfers of cryopreserved embryos. METHODS: Four IVF centres allocated 426 patients, randomized for AH
and IA, into four groups of AH indications between 1997 and 1999. AH was performed with a diode laser. ZP
thickness, opening size and embryo score were recorded. Outcome measures were implantation and delivery rates.
RESULTS: Patients coming for a first or third transfer of cryopreserved embryos and poor prognosis patients
admitted for a first trial did not benefit from AH. Even patients with repeated implantation failures of fresh
embryos did not gain significantly from AH. CONCLUSIONS: Among AH indications, absence of implantation
after several transfers of good quality embryos remains the strongest patient selection criterion. Prescription of an
immunosuppressive/antibiotic treatment is essential.
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Introduction
Less than 20% of unselected human embryos replaced in the
uterus after IVF are able to produce viable pregnancies. Sev-
eral cumulative factors have been considered to lower the
implantation rates: poor in vitro culture conditions of clea-
vage stage embryos (Bongso et al., 1991), a high rate
of aneuploidy observed in human oocytes and embryos
(Plachot, 1992; Gianaroli et al., 1999), a controversial
reduction of endometrial receptivity (Abdalla et al., 1994;
Baruffi et al., 2002) and/or an inability of the blastocyst to
escape from its zona pellucida (ZP) (Cohen, 1993; De Vos
and Van Steirteghem, 2000). Thinning or opening of the ZP
using chemical (Cohen et al., 1992; Tao and Tamis, 1997),
mechanical (Stein et al., 1995; Chao et al., 1997), enzymatic
(Isik et al., 2000), piezo-micromanipulation (Nakayama et al.,
1999) or laser (Germond et al., 1999) methods have been
performed for over a decade to assist blastocyst hatching and
favour its implantation (Cohen, 1991). An infrared laser
method allowing a rapid, precise and non-touch micro-
dissection of the ZP protein matrix (Rink et al., 1994, 1996)
has progressively replaced the previously described assisted
hatching (AH) techniques. Selective AH using the four
methods mentioned above was shown to yield similar
implantation and pregnancy rates (Balaban et al., 2002).
Thick or hardened ZP (Cohen et al., 1992; De Vos and
Van Steirteghem, 2000) are considered as two major causes
able to impede the hatching process. However, the indi-
cations for AH remain elusive and several prospective and
retrospective studies have failed so far to demonstrate which
indications clearly benefit from AH (Germond et al., 2000;
Edi-Osagie et al., 2003).
A possible hazard of AH is that it deprives the embryo
of its protective ZP. Immunosuppression by corticosteroids
was initially shown to favour implantation of ZP dissec-
ted embryos (Cohen et al., 1990). However, when given
to patients receiving a transfer of non-micromanipulated
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embryos, the immunosuppressive treatment was found either
to have no clinical benefits (Lee et al., 1994) or to signifi-
cantly enhance implantation (Polak de Fried et al., 1993).
The two aims of the present study, involving four
European IVF centres, were to assess the benefit of laser AH
in four groups of patients with distinct AH indications and to
value the usefulness of an associated immunosuppressive
therapy.
Materials and methods
The four IVF centres involved were: (i) the Reproductive Medicine
Unit in the CHUV of Lausanne, Switzerland; (ii) the Department of
Gynaecology and Reproductive Medicine of the University of Bonn,
Germany; (iii) the IVF and Reproductive Biology Laboratory of the
Necker Hospital in Paris, France; and (iv) the Dexeus Institute in
Barcelona, Spain.
Patients
A pre-study visit took place 2 months before the enrolment in the
study, during which the prospective patient was informed of the
study’s objectives and overall requirements, received an information
document and went through a clinical evaluation to ensure con-
formity with the eligibility criteria. The inclusion criteria were: (i)
aged between 20 and 45 years old, (ii) having at least one functional
ovary, (iii) having normal FSH (between 3 and 12 IU/l) and prolac-
tin (,30mg/l) levels, (iv) having no clinically significant abnormal
findings within 6 months before treatment start, (v) having no pelvic
inflammatory disease between the previous assessment and study
entry, (vi) having a normal uterine cavity as documented within
5 years prior to treatment assignment by a hysteroscopy, hystero-
salpingography or hysterosonography, (vii) being able to communi-
cate well with the investigator and to comply with the requirements
of the entire study, and (viii) having given written informed consent
prior to treatment with the understanding that consent may be with-
drawn by the patient at any time without prejudice.
The pre-study visit included the following: recording of demo-
graphic data, medical and medication history, gynaecological and
obstetrical history, physical and gynaecological examinations, diag-
nostic ultrasound, and blood tests [FSH, prolactin (PRL), rubella,
hepatitis B and C, HIV].
Depending on their specific AH indications, eligible patients were
allocated by the supervising medical doctor to one of the treatment
groups (I, II, III or IV) described below, and randomized at the
beginning of the menstrual cycle during which the embryo transfer
was going to take place.
Group I: patients who initiated their first transfer cycle of frozen-
thawed embryos. AH was performed or not according to a random-
ization list (Figure 1A).
Group II: patients who had failed to conceive in at least two
transfer cycles of frozen-thawed embryos and were initiating a third
transfer cycle of thawed embryos. AH was performed on all trans-
ferred embryos (Figure 1B).
Group III: a selected group of patients who had a poor prognosis
of conception (age .37 years old or FSH .10 UI/l) for their
first transfer of fresh embryos. AH was performed according to a
randomization list (Figure 1A).
Group IV: a selected group of patients who had experienced three
previous nidation failures of fresh embryos, including each time the
transfer of at least two embryos of good quality, and were initiating
their fourth transfer cycle of fresh embryos. AH was performed on
all transferred embryos (Figure 1B).
For ethical reasons all patients in Groups II and IV received the
laser treatment. Therefore, historical control groups with patients
treated during the same period of time and presenting the same
inclusion criteria were built up retrospectively for these two groups.
In all four groups, the patients receiving laser-drilled embryos
were further randomized in a double-blind trial, testing the role of
an immunosuppressive/antibiotic treatment (IA) versus placebo (P)
(Figure 1).
The patient data were collected in each centre on case report
forms (CRFs). Regularly the CRFs were sent to the principal inves-
tigator of the study in Lausanne and data from each patient were
reviewed and stored in a computerized database (FileMaker Pro,
Filemaker Inc., USA) for further analysis.
The patient’s anonymity was maintained, as patients were
identified on CRFs by their initials and a code number. The co-
investigators kept a record of patient’s name, address and code and
only the CRFs bearing the patients’ initials were sent to the princi-
pal investigator for analysis.
During the course of the treatment, the patient might have been
discontinued for the following reasons: lack of ovulation, serious
adverse effects, major protocol violation, discovery of ineligibility,
non compliance, administrative reasons and pregnancy.
AH using the 1.48mm diode laser
The four centres involved in the study used the same laser
device (Fertilase, Medical Technologies Montreux S.A., Clarens,
Switzerland), which was installed on each co-investigator’s inverted
microscopes (Rink et al., 1994). The ZP was opened by drilling a
tangential trench using a similar strategy. The culture dish was
placed on the heated displacement stage of the microscope and a
region of the ZP, adjacent to a wide perivitelline space, was posi-
tioned at the location of the aiming spot. The ZP was fully dissected
by 1–4 laser shots, in order to create a single breach presenting a
width close to that of the ZP. Sizes of the drilled holes could be
adapted by varying the irradiation time; typically a trench having a
diameter of 20mm was produced by a 12–30 ms irradiation time
(Rink et al., 1996). Because of the short irradiation time needed, no
micromanipulators were necessary to stabilize the oocyte’s position
during the drilling procedure. When larger holes involving several
Figure 1. (A) Randomization scheme for Groups I and III. (B) Ran-
domization scheme for Groups II and IV.
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laser shots were to be drilled, the embryos were placed in a
20–50ml drop of medium under mineral oil; undesirable displace-
ments of the embryos due to thermal convection that are generally
present inside larger culture dishes could thus be avoided. Accord-
ing to our previous experience on mouse embryos (Germond et al.,
2000), the ZP has to be fully breached to be effective compared to
local thinning, thus a hole diameter equal or superior to ZP thick-
ness was recommended for ZP drilling in the study. However, it has
been shown that thinning of the ZP, but on a wider area (a quarter
of the ZP), was more effective than total breaching and local thin-
ning (Mantoudis et al., 2001).
The safety and efficacy of the method have been previously estab-
lished by determining the ability of mouse oocytes to fertilise
in vitro and develop in vivo (Germond et al., 1995, 1996).
Fresh embryo transfer
Embryo transfers were performed on day 2 or 3 according to each
centre’s practice. AH was performed a few hours before embryo
transfer. On that occasion, the embryos were examined and scored
by recording the number and regularity of the blastomeres as well
as the amount of extracellular fragments (Senn et al., 2000). The ZP
thickness was measured on four opposite sides.
Progesterone was administered vaginally as a luteal phase sup-
plementation and continued daily up to menstruation or for 10
weeks in pregnant patients.
Frozen-thawed embryo transfers
Zygotes or embryos were cryopreserved according to the same
protocol in all centres, using propanediol as cryoprotectant, manual
seeding at 278C, and a slow freezing procedure lasting ,90 min
(from 228C to 21508C). The devices used to perform the freezing
were ‘Air Liquide Minicool 40 PC’ (Switzerland and Spain), ‘Air
Liquide LC 40’ (France) and ‘Labotect CTE 90’ (Germany). Again,
the thawing procedures were the same in all four centres. Zygotes
cryopreserved at the pronucleate stage were thawed 1 day before
embryo transfer in order to allow for the first cleavage to take place.
Embryos cryopreserved at the cleavage stage were thawed according
to their development stage at freezing and transferred accordingly.
Transfers of frozen-thawed embryos were performed in natural or
artificial cycles. AH and embryo transfers were performed under
conditions similar to those used for fresh embryos.
Drug treatment
The additional medication consisted of methylprednisolone 16 mg
(Medrolw, Pharmacia & Upjohn AG, Switzerland) and doxycycline
200 mg (Supracyclinew, Gru¨nenthal Pharma AG, Switzerland)
which were given 2 days prior and up to 5 days after ET. According
to a randomization list, the pharmacy at the CHUV prepared for
each patient the set of drugs necessary for completing one treatment
cycle. All drugs were reconditioned in packages, allowing full blind-
ing both for the medical staff and the patient.
Figure 2. Flow diagram of the multicentre trial comparing the effect of assisted hatching on four different patient populations.
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Randomization
The number of cases (n) necessary to achieve statistical significance
(P , 0.05) when a 20% increase in pregnancy rate after AH is
expected was estimated as follows:
Group I: Control (n ¼ 70); AH þ P (n ¼ 70); AH þ IA (n ¼ 70)
Group II: AH þ P (n ¼ 70); AH þ IA (n ¼ 70)
Group III: Control (n ¼ 50); AH þ P (n ¼ 50); AH þ IA (n ¼ 50)
Group IV: AH þ P (n ¼ 50); AH þ IA (n ¼ 50)
Groups I and III were randomized both for AH and medication
according to the scheme described in Figure 1A. Groups II and IV
were randomized only for IA because all patients received AH, as
shown in Figure 1B. Computer-generated randomization lists were
drawn up separately for AH and drug assignments for each treatment
group. The information relative to the AH procedure was sent to the
centres by lists of 10 case numbers in sealed envelopes. The local
medical supervisors in charge of the study allocated the next avail-
able case number on the list to each admitted couple and distributed
the box of tablets bearing the same case number. Case numbers and
patient initials were recorded by the study supervisor on the CRF
and were used as means to unequivocally identify a patient.
According to the CONSORT (Consolidated Standards of Report-
ing Trials) statement for randomized studies (Altman et al., 2001), a
flow diagram of the progress through the phases of this randomized
trial is provided in Figure 2. Out of the 600 patients initially
expected, 466 could be considered eligible by the co-investigators
and 426 were randomly allocated between January 1997 and
December 1999. The study was prematurely interrupted due to
recruitment difficulties.
Blinding
Participants and medical supervisors were blinded in respect to both
the AH procedure and the IA treatment. Patients were only aware of
the group they had been allocated to. Laboratory staff was necess-
arily aware of the AH assignment according to the randomization
list, but was blind to the IA/placebo treatment. The randomization
list for the drug treatment was kept by the pharmacy department of
the CHUV and unveiled at the end of the study.
Outcome measures
The primary outcome measure was the occurrence of a clinical preg-
nancy diagnosed by elevated serum hCG levels and the presence of
at least one fetal sac exhibiting cardiac activity. The clinical preg-
nancy (CPR) and implantation (IR) rates were calculated for each
subgroup of patients (Control, AH þ P and AH þ IA). Assessment
of efficacy and safety were also based on the following secondary
outcome measures: live births, abortions, multiple pregnancies, bio-
chemical pregnancies (miscarriage without evidence of a fetal sac
on ultrasound and hCG levels remaining ,1000 UI/l and reaching
undetectable values 3 weeks after transfer).
Statistical analysis
Chi-square and Student’s t-test were calculated wherever appropriate
with the StatView Student statistical package. Differences were con-
sidered as significant when P reached values ,0.05.
Results
Table I summarizes some relevant clinical aspects of the trea-
ted patients in the four groups. Patients in Groups I and II
were comparable in terms of age, body mass index (BMI),
occurrence of primary infertility and smoking habit, as well
as IVF indications. Patients in Groups III and IV were sig-
nificantly older (P , 0.05) and presented a higher incidence
of idiopathic causes of infertility (P , 0.05).
The clinical outcome of the transfers in the four groups
of patients treated is presented in Table II. In Group I
(Table IIA), significantly lower pregnancy (1.6% versus
15.1%; P ¼ 0.0195) and implantation (1.6% versus 10.0%;
P ¼ 0.0106) rates were obtained in the subgroup of patient
receiving laser-drilled embryos and a placebo (AH þ P) com-
pared to the control. These rates were restored to those of the
control (10.7% versus 15.1% and 6.0% versus 10.0%) when
AH was accompanied by corticosteroid/antibiotic adminis-
tration (AH þ IA). All other parameters, such as age, number
of transferred embryos and ZP thickness did not differ sig-
nificantly among the three subgroups (control, AH þ P and
AH þ IA). The mean hole diameters of the AH embryos
were close to the mean ZP thickness and statistically similar
in both subgroups AH þ P and AH þ IA.
In Group II (Table II.B.), both clinical pregnancy (7.9%
versus 10.8%) and implantation rates (5.1% versus 4.8%) did
not differ among the patients in AH þ IA and AH þ P.
These rates were furthermore quite similar to the historical
control group. As for Group I, all other parameters recorded
did not differ significantly among the three subgroups of
patients.
Among the poor prognosis patients (Group III, Table IIC),
slightly lower but not statistically different rates in the clini-
cal pregnancies and implantation were observed in the
AH þ P subgroup compared to the control (13.6% versus
23.8% and 6.4% versus 9.1%) and to the AH þ IA subgroup
(13.6% versus 21.7% and 6.4% versus 9.1%). The AH þ IA
subgroup yielded rates similar to the control. However, the
‘take home baby rate’ was increased, but not significantly,
after AH þ IA due to only one abortion in this subgroup
compared to four in the control one.
Finally, in Group IV (Table IID), both clinical pregnancy
(16.7% and 14.3% versus 11.4%) and implantation (7.5%
and 6.3% versus 5.2%) rates were slightly higher after
AH þ IA and AH þ P compared to the historical control
group. As for the other groups, all other parameters recorded
Table I. Clinical data regarding the four groups of treated patients
Groups
I II III IV
Number of
expected patients
210 140 150 100
Number of treated
patients
171 75 66 65
Age (mean ^ SD) 32.4 ^ 3.9 32.3 ^ 4.0 39.3 ^ 2.8 35.1 ^ 4.1
BMI (mean ^ SD) 22.5 ^ 3.7 21.7 ^ 3.1 23.5 ^ 4.1 22.7 ^ 3.8
Smokers 39% 34% 36% 23%
Primary infertility 73% 68% 63% 72%
IVF indications, n(%)
Female 52 (30.4) 31 (41.3) 26 (39.4) 14 (21.5)
Male 97 (56.7) 30 (40.0) 18 (27.3) 34 (52.3)
Mixed 11 (6.4) 9 (12.0) 5 (7.6) 4 (6.2)
Idiopathic 11 (6.4) 5 (6.7) 17 (25.8) 13 (20.0)
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did not differ significantly among the three subgroups of
patients.
In order to reduce the confounding influence of the embryo
quality, data from Groups I and II were pooled and the pool
of transfers meeting the following criteria was extracted:
(i) cryopreservation was performed at the pronucleate stage;
(ii) transfers, performed on day 2 or 3 contained at least one
good quality embryo (day 2: four blastomeres with no or
Table II. Clinical outcome of the embryo transfers in the four groups of patients
A: Group I Control AH þ P AH þ IA
Number of patients 53 62 56
Mean age (years) 32.6 ^ 3.8 32.8 ^ 4.2 31.7 ^ 3.7
Total embryos transferred 110 127 116
ZP thickness (mm) 17.9 ^ 3.3 17.3 ^ 3.1 17.0 ^ 2.4
Hole diameter (mm) 17.9 ^ 6.1 18.0 ^ 7.1
Mean embryos transferred 2.1 ^ 0.7 2.0 ^ 0.7 2.1 ^ 0.7
Biochemical pregnancies n (%) 3 (5.7) 1 (1.6) 2 (3.6)
Clinical pregnancies n (%) 8 (15.1)a 1 (1.6)a 6 (10.7)
Abortions n 1 0 2
Deliveries n (%) 7 (13.2) 1 (1.6) 4 (7.1)
Multiple pregnancies n 3 1 1
Number of sacs n 11 2 7
Implantation rate n(%) 10.0b 1.6b 6.0
B: Group II Historical control AH þ P AH þ IA
Number of patients 45 37 38
Mean age (years) 31.3 ^ 3.3 33.3 ^ 4.2 31.4 ^ 3.5
Total embryos transferred 88 83 79
ZP thickness (mm) 17.2 ^ 4.6 17.4 ^ 4.2
Hole diameter (mm) 18.0 ^ 11.4 18.4 ^ 11.6
Mean embryos transferred 2.0 ^ 0.7 2.2 ^ 0.6 2.1 ^ 0.7
Biochemical pregnancies n(%) 0 (0.0) 0 (0.0) 0 (0.0)
Clinical pregnancies n (%) 4 (8.9) 4 (10.8) 3 (7.9)
Abortions n 0 0 0
Deliveries n (%) 4 (8.9) 4 (10.8) 3 (7.9)
Multiple pregnancies n 1 0 1
Number of sacs n 5 4 4
Implantation rate (%) 5.7 4.8 5.1
C: Group III Control AH þ P AH þ IA
Number of patients 21 22 23
Mean age (years) 38.3 ^ 3.4 39.3 ^ 2.9 40.1 ^ 2.0
Total embryos transferred 55 47 55
ZP thickness (mm) 16.9 ^ 3.6 16.4 ^ 3.6 15.8 ^ 4.2
Hole diameter (mm) 16.8 ^ 8.5 16.5 ^ 11.1
Mean embryos transferred n 2.6 ^ 0.5 2.1 ^ 0.9 2.4 ^ 0.7
Biochemical pregnancies n (%) 4 (19.0) 0 (0.0) 1 (4.3)
Clinical pregnancies n (%) 5 (23.8) 3 (13.6) 5 (21.7)
Abortions n 4 1 1
Deliveries n (%) 1 (4.8) 2 (9.1) 4 (17.4)
Multiple pregnancies n 0 0 0
Number of sacs n 5 3 5
Implantation rate n (%) 9.1 6.4 9.1
D: Group IV Historical control AH þ P AH þ IA
Number of patients 44 30 35
Mean age (years) 34.4 ^ 4.1 34.5 ^ 3.8 35.6 ^ 4.2
Total embryos transferred 115 80 96
ZP thickness (mm) 16.9 ^ 3.1 16.7 ^ 4.5
Hole diameter (mm) 18.0 ^ 3.2 18.0 ^ 8.0
Mean embryos transferred 2.6 ^ 0.7 2.7 ^ 0.5 2.7 ^ 0.4
Biochemical pregnancies n (%) 1 (2.3) 2 (6.7) 2 (5.7)
Clinical pregnancies n (%) 5 (11.4) 5 (16.7) 5 (14.3)
Abortions n 2 1 1
Deliveries n (%) 3 (6.8) 4 (13.3) 4 (11.4)
Multiple pregnancies n 1 1 0
Number of sacs n 6 6 6
Implantation rate (%) 5.2 7.5 6.3
Control: intact embryos; AH þ P: laser drilled embryos with placebo; AH þ IA: laser drilled embryos with
immunosuppressive/antibiotic treatment; Historical control: intact embryos.
aP ¼ 0.0195.
bP ¼ 0.0106.
Diode laser for assisted hatching and immunosuppression in a randomized study
2329
Table III. Clinical outcome of selected transfers containing at least one
embryo of good quality (4I-4II on day 2 or 8I-8II on day 3) after
cryopreservation at the pronucleate stage, Groups I and II combined
Groups I and II Control AH þ P AH þ IA
Number of patients 46 29 34
Mean age (years) 31.0 ^ 3.8 33.4 ^ 3.9 31.2 ^ 3.2
Total embryos transferred 96 64 67
ZP thickness (mm) 15.9 ^ 3.2 16.9 ^ 4.5
Mean embryos transferred 2.1 ^ 0.6 2.2 ^ 0.6 2.0 ^ 0.6
Biochemical pregnancies n (%) 2 (4.3) 2 (6.9) 1 (2.9)
Clinical pregnancies n (%) 9 (19.6) 2 (6.9) 5 (14.7)
Abortions n 1 (11.1) 1 (50.0) 1 (20.0)
Deliveries n (%) 8 (17.4) 1 (3.4) 4 (11.8)
Multiple pregnancies n 3 (33.3) 0 (0.0) 0 (0.0)
Number of sacs n 12 3 5
Implantation rate (%) 12.5 4.7 7.5
Control: intact embryos; AH þ P: laser drilled embryos with placebo;
AH þ IA: laser drilled embryos with immunosuppressive/antibiotic
treatment.
Figure 3. Scattergram of the ZP thickness in relation to age of the patient at OPU. n ¼ 363.
Figure 4. Scattergram of the ZP thickness (in mm) in relation to basal FSH (UI/l) of the patient. Restricted to those patients for which the
value of the FSH level was known. n ¼ 192.
Table IV. Clinical outcome of all transfers, fresh and cryopreserved
combined, classified according to the mean ZP thickness of the transferred
embryos and to the type of medication.
All groups Mean ZP thickness P
,17mm 17mm
Cycles AH þ P n 71 78
Clinical pregnancies 6/71 (8.5%) 6/78 (7.7%) NS
Implantation rates 7/158 (4.4%) 7/174 (4.0%) NS
Cycles AH þ IA n 78 73
Clinical pregnancies 10/78 (12.8%) 9/73 (12.3%) NS
Implantation rates 11/180 (6.1%) 11/163 (6.7%) NS
AH þ P: laser drilled embryos with placebo; AH þ IA: laser drilled
embryos with immunosuppressive/antibiotic treatment. Diode laser for
assisted hatching and immunosuppression in a randomized study.
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little fragments; day 3: eight blastomeres with no or little
fragments). Clinical outcome of the embryo transfers are pre-
sented in Table III. No significant difference was observed
between the subgroups in terms of clinical pregnancy and
implantation rates, although AH in the absence of immuno-
suppressive treatment led to a lower pregnancy rate (6.9%
versus 19.6%).
The relationship between ZP thickness and age of the
patients at OPU has been studied by combining the values
measured in all groups. The scattergram presented in Figure 3
indicates that the ZP thickness was not related to the age of
the patients in the study population. A similar observation
can be made when the ZP thickness is expressed relatively to
the basal FSH level (Figure 4).
In order to test whether the ZP thickness was related to the
clinical outcome after AH, pregnancy and implantation rates
have then been calculated when the mean ZP was ,17mm
or above. Results, presented in Table IV, indicate that both
rates were similar when AH was performed on thin or thick
ZP, independently of the IA treatment.
The implantation rates of the embryos having been treated
with AH in all the groups were studied in relation to the size
of the hole performed for AH (Figure 5). Although the rates
showed no statistical difference, the embryos with the dia-
meter of the hole the nearest to the ZP thickness (Hole
diameter/ZP thickness close to 1) were implanting with a
higher rate than the ones with a smaller or a bigger opening.
The numbers of biochemical pregnancies and abortions
were too small to draw any conclusions and the values
obtained were comparable among the subgroups and between
the groups (Table IIA–D).
Discussion
The data obtained in this prospective randomized study indi-
cate that AH does not lead to higher implantation rates in
older patients (Group III) and in patients initiating a cryo
cycle (Groups I and II). In two groups, I and III, AH treat-
ment appears to have a negative effect when not supported
by IA therapy. When AH is performed on fresh embryos
after repeated implantation failures (Group IV), the implan-
tation and clinical pregnancy rates are both improved
although not significantly. In the latter case, the IA treatment
does not add any positive effect on the rates.
Recruitment of the patients for this study appeared much
more difficult than initially anticipated. The study had thus to
be ended before the expected number of patients (n ¼ 600)
was reached. Despite the premature ending of the study,
there was no negative impact on the statistical significance of
the data.
The study was elaborated in order to confirm results
obtained on smaller groups of patients in two of the
European centres. One study performed in the IVF centre of
Lausanne on a group of patients similar to Group II had
shown that patients receiving a transfer of good quality fro-
zen-thawed embryos gained from the ZP microdissection
treatment compared to control (Germond et al., 2000). When
the embryo quality was high (CES 20), AH increased IR
from 3.6% to 14.7% and CPR from 10.5% to 29.6%. Sixteen
deliveries were obtained with the birth of 22 healthy children
in the AH group, compared to four deliveries and four child-
ren in the control group (Germond et al., 2000). However,
when the four IVF centres tried to confirm these findings, the
results were very different and no improvement was observed
after AH even in good score embryo transfers. The other
prospective study performed in the IVF centre of Bonn, on
two groups of patients with advanced maternal age, demon-
strated that AH increased both implantation and clinical preg-
nancy rates (Montag and van der Ven, 1999). There again,
these findings were not confirmed in the multicentre study
where AH did not improve the clinical outcome of older
patients. However, it should be noted that in the study by
Montag and van der Ven (1999), although patients were
selected according to maternal age, they had also failed treat-
ment cycles in their past, so that it is not possible to compare
these results directly to those of Group III in the multicentre
study.
In general, the disparity between the positive results of
these two small (small number of patients and/or study per-
formed in a single centre) prospective but not randomized
studies and the null ones obtained in the multicentre random-
ized study with similar groups of patients shows that the
results obtained within a group of patients, in a particular
laboratory and with a specific technique, cannot be genera-
lized. In the same way, several clinical studies have been per-
formed for the last decade in different IVF centres and
demonstrated that AH could either have a positive or a null
effect on IR and CPR rates when the same groups of patients
were selected (Germond et al., 1999). Similarly to the present
work, a multicentre study (two IVF centres) reported that AH
was unable to benefit patients selected for advanced age,
zona thickness and previous multiple failures in both fresh
and frozen-thawed embryos (Edirisinghe et al., 1999). How-
ever, two meta-analyses by Edi-Osagie et al. (2003) and
Sallam et al. (2003) show a positive trend of AH for patients
similar to those of Group IV with repeated implantation
failures.
Figure 5. Implantation rates after transfers of embryos receiving
assisted hatching with different hole sizes in patients treated (IA) or
not (Placebo) with the immunosuppressive/antibiotic treatment.
NS ¼ not significantly different.
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It is obvious in this study that patients receiving a transfer
of ZP microdissected embryos needed a concomitant admin-
istration of an immunosuppressive/antibiotic therapy. The
treatment of patients with corticosteroids may prevent some
undefined antibodies or surveillance cells from gaining access
to and destroying the embryos. This may be especially
important after zona drilling (Cohen et al., 1990) or blasto-
cyst natural hatching when the embryo is left exposed to
uterine lymphocytes and immune cells.
Secondary objectives were to establish the roles of the
morphological characteristics of the transferred embryos, the
ZP thickness and the opening diameter on the implantation
rates and to initiate a follow-up of the pregnancies up to
delivery. It is possible that the efficacy of AH depends less
on the clinical variables of the patients than on the morpho-
logical characteristics of oocytes and embryos (Montag et al.,
2000; Ebner et al., 2002). AH is not going to ameliorate the
poor quality of an embryo or improve its development up to
the blastocyst stage. A better selection of the embryos
already guarantees higher implantation and clinical preg-
nancy rates. However, in the present work, no embryo selec-
tion was performed in Lausanne and Bonn due to legal
restrictions and all the embryos, kept fresh in culture or
thawed, were transferred. This might explain why the
implantation rates observed in this study were much lower
than those obtained when embryo selection is common
practice.
The safety of the laser had already been proved in animal
studies first (Germond et al., 1995, 1996) and then in humans
(Germond et al., 2000). The results of this study show that
the AH treatment does not increase the abortion rate or the
number of biochemical pregnancies, thus confirming the
safety of the technique. A children follow-up study (results
not published) has been performed in the Lausanne IVF
centre on 51 deliveries and 62 babies born after AH and
looking at prenatal karyotypes, sex ratio, birth parameters,
major and minor congenital malformations and physical
examinations of the children after birth and 4–6 weeks later.
No higher risks for incidence of congenital malformation and
chromosomal aberration were found in that group of children
compared to control. A similar study was performed in
Budapest (Kanyo and Konc, 2003) with 96 deliveries and
134 babies born, which conclude the same results.
The number of multiple pregnancies was not higher in the
AH treated patients than in the control patients. One fear is
that AH could increase the incidence of monozygotic twin-
ning (MZT) due to a partial hatching of the conceptus
through the hole made in ZP causing a herniation and a div-
ision into two embryos. Several studies have been published
which tend to demonstrate that the frequency of MZT is not
different after the transfers of ‘zona manipulated’ embryos
compared to ‘zona intact’ ones (Sills et al., 2000) and that if
the rate of MZT is increased after assisted reproduction, it is
irrespective of the treatment modality or the type of micro-
manipulation (Schachter et al., 2001). Only a few trials
reported an increase in MZT after AH (Hershlag et al., 1999;
Yakin et al., 2003) and most of them are case reports
(Schieve et al., 2000; Sheen et al., 2001). Three other studies
(Behr et al., 2000; da Costa et al., 2001; Milki et al., 2003)
showed that transfers at the blastocyst stage were the main
reason for an increase in the frequency of MZT.
In conclusion, this study did not succeed in clearly identi-
fying one or more groups of patients in need of AH treat-
ment, neither in designating the embryos with specific
morphometric characteristics that predestined them to hatch-
ing failure. Patients with repeated unexplained IVF failure
constitute the main target group for ZP microdissection, but
ideally the patients or the embryos requiring AH should be
identified before the unsuccessful attempts. Clinically, the
indications for AH still have to be weighed according to a
series of confounding variables, such as the number of unsuc-
cessful embryo transfers, the patient’s age, the morphological
characteristics of the embryo and the ZP, keeping in mind
that no harm can be done to the embryo by practising AH,
that the incidence of monozygotic twinning is not increased
and that the implantation is not impaired as long as an immu-
nosuppressive/antibiotic treatment is prescribed.
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